A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Sponsor
Eli Lilly and Company
Study ID
NCT07313813
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
21 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.

Key Dates

Start date
Dec 29, 2025
Status verified
Apr 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Dulaglutide (LY2189265)-Solid-Meal
    Administered subcutaneously (SC)
  • Experimental: Dulaglutide (LY2189265)-Liquid-Meal
    Administered SC

Primary Outcome Measure

Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal [ Time Frame: Day 116 (at 6, 8, 12, 18 and 24 hours after baseline or Day 115 solid test meal) ]

Related Studies